A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Clinical Activity of ABS-1230 in Pediatric and Young Adult Participants With KCNT1-related Epilepsy

Study acronym: KYRON
StatusRecruiting
PhasePhase 2
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Enrollment increased: 55 → 61 participants
    • Study sites: 1 to 2
    • Eligibility criteria expanded, about 6 words
  2. Enrollment increased: 45 → 55 participants
    • Study title expanded, about 3 words
    v4
  3. Site contact updatedv3
  4. Start date changed from estimate of May 2026 to May 18, 2026v2
  5. Study First Submitted
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This trial will evaluate the safety, tolerability, pharmacokinetics, and clinical activity of ABS-1230 compared with placebo in participants with KCNT1-related epilepsy
Trial Details
NCT Number NCT07600736
Lead Sponsor Actio Biosciences, Inc.
Conditions
(from sponsor)		 KCNT1-Related Epilepsy
Enrollment 61 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov